openheart β -Alanine and orotate as supplements for cardiac protection

Mark F McCarty,¹ James J DiNicolantonio²

To cite: McCarty MF, DiNicolantonio JJ. β -Alanine and orotate as supplements for cardiac protection. *Open Heart* 2014;1:e000119. doi:10.1136/openhrt-2014-000119

Accepted 15 July 2014

CARNOSINE: ACID BUFFER, ANTIOXIDANT AND AID TO MUSCLE CONTRACTION

β -Alanine is a rate-limiting precursor for synthesis of the dipeptide carnosine (β -alanyl-L-histidine), which is produced within and stored in high concentrations in skeletal muscle, heart and olfactory receptor neurons.^{1 2} β -Alanine supplementation has been shown to boost the carnosine content of skeletal muscle.³ This reflects the fact that the K_m of carnosine synthase for β -alanine (in excess of 1 mM) is far higher than the β -alanine content of tissues; its K_m for histidine is two orders of magnitude lower, such that intracellular histidine levels are not rate-limiting for carnosine synthesis.³ β -alanine is produced in the liver during catabolism of uracil; after its release to plasma, it can be transported into tissues that require it for carnosine synthesis. Plasma levels of β -alanine also increase when carnosine is ingested in flesh foods; particularly in humans, carnosinase activity in plasma rapidly cleaves carnosine to its precursors β -alanine and histidine.⁴ The pK_a of the imidazole ring of carnosine is 6.83, which makes it an ideal physiological buffer for tissues when glycolytic production of lactic acid is high.³ (The pK_a of free histidine's imidazole ring is around 6, so converting histidine to carnosine makes it a more effective buffer.) Most studies with supplemental β -alanine have focused on skeletal muscle and athletic performance; many studies have concluded that β -alanine supplementation can both boost muscle carnosine content and aid performance in high-intensity anaerobic workouts in which lactic acid is generated, presumably by preventing counterproductive reductions in intracellular pH.³ The fact that carnosine concentrations in fast-twitch muscles are higher than those in slow-twitch muscles is consistent with this paradigm.

Carnosine also has versatile antioxidant activity, likewise reflecting the properties of its imidazole ring. This can serve efficiently as an electron donor, preventing lipid peroxidation; it also quenches singlet oxygen and interacts with superoxide in a way that stabilises it.^{5 6}

Like histidine, carnosine can chelate copper and iron, and this chelation prevents these ions from catalysing Fenton chemistry, hence blocking production of hydroxyl radicals.⁵ Moreover, carnosine-copper complexes possess superoxide dismutase activity.⁷ Further, carnosine binds covalently to reactive degradation products of peroxidised lipids, preventing them from reacting with other cellular targets.⁸

Carnosine may also function in skeletal muscle and heart to amplify the impact of cytoplasmic calcium on muscular contraction.^{9 10} It seems to do so by sensitising the contractile apparatus to free calcium; some, but not all, studies suggest that it also can upregulate calcium release from the sarcoplasmic reticulum.

BOOSTING CARDIAC CARNOSINE AS A STRATEGY FOR CARDIOPROTECTION

Cardiac muscle manufactures carnosine and related derivatives of histidine; most of these are *N*-acetylated.^{11 12} The intracellular levels of these histidine derivatives in cardiac muscle is about 10 mM, likely reflecting a key need for their buffering activity when oxygen availability fails to meet the need for ATP production and glycolytic lactic acid production compensatorily increases. Moreover, the versatile antioxidant activity of carnosine and related histidine compounds produced in the heart also seems likely to be cardioprotective.^{13 14} Indeed, exogenous carnosine has been shown to protect cardiac tissue from ischaemia-reperfusion damage, and is also protective for doxorubicin-induced cardiomyopathy.^{15–21} Further, the procontractile impact of carnosine would be of potential value in congestive failure.

It is reasonable to suspect that supplemental β -alanine would boost cardiac stores of carnosine and *N*-acetylcarnosine, although studies documenting this do not appear to be available. This follows from the fact that the K_m for β -alanine of carnosine synthetase—known to be expressed in cardiac muscle, albeit at a lower level than in skeletal

¹Catalytic Longevity, Carlsbad, California, USA

²Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA

Correspondence to

Dr James J DiNicolantonio; jdinicol@gmail.com

Figure 1 Cardioprotective potential of orotate.

muscle²²—is above 1 mM; although it is difficult to find studies that have measured heart β -alanine levels, the level of other free amino acids in the heart is in the low micromolar range.²³ Moreover, β -alanine released by the liver or supplied from the diet should have access to cardiomyocytes, since it is carried across membranes by the taurine transporter, vital for cardiac function.^{24–25} Given carnosine's antioxidant, acid-buffering and procontractile activities, dietary measures that boost cardiac levels of carnosine and *N*-acetylcarnosine could be expected to be protective in disorders such as myocardial infarction, angina and congestive failure; however, the extent to which this would be of clinical significance remains to be clarified. With respect to the acid-buffering activity of carnosine and its derivatives, it is pertinent to note that the clinical utility of carnitine in cardiac ischaemia may be largely attributable to its ability to promote mitochondrial oxidation of pyruvate, hence lessening glycolytic generation of lactic acid.²⁶

To date, clinical studies evaluating the utility of supplemental β -alanine or carnosine in cardiac disorders appear to be lacking. However, dietary β -alanine presupplementation in rats subsequently subjected to 45 min of left main coronary occlusion was found to be associated with a 57% reduction in infarct size to risk area ratio.²⁷ Although the authors attributed this effect to moderate taurine depletion of the heart induced by the high β -alanine intake (3% in drinking water), they did not consider the possible role of carnosine and *N*-acetylcarnosine in this phenomenon.

OROTATE AS A CARNOSINE PRECURSOR

Of possible pertinence is an intriguing literature documenting that supplemental magnesium orotate is clinically useful in congestive failure and angina.^{28–31} In particular, a placebo-controlled study evaluating magnesium orotate (6 g daily for 1 month, 3 g daily for 11 months) in patients with severe congestive failure, reported a 75.7% survival rate in the orotate treated patients, as opposed to 51.5% survival in those receiving placebo ($p < 0.05$).³¹ Orotates are also beneficial in a hamster model of inherited cardiomyopathy.³² The explanation typically offered for the utility of this agent in cardiac conditions is that the stressed heart benefits from an increased pool of pyrimidine nucleotides; oral orotate is taken up by the liver and is converted to uridine, some of which reaches the plasma and can be taken up by cardiac tissue.^{28–33} The magnesium in this complex is also thought to benefit the failing heart.³⁴ But why pyrimidines should be so beneficial to the heart has never been clear. This explanation is somewhat

difficult to square with the observation that orotic acid supplementation only transiently and modestly increases the pyrimidine pool in the heart, yet it aids contractile recovery after global ischaemia and prevents loss of adenine nucleotides.³³ Perhaps the difficulty in explaining the basis of orotate's protective activity has resulted in this important research receiving less attention than it deserves.

As an alternative or additional explanation, it should be noted that absorbed orotate is ultimately converted to β -alanine. After orotate is employed in uridine synthesis in the liver,^{33–35} uridine is eventually broken down to yield free uracil. The catabolism of uracil involves its successive conversion to dihydrouracil, β -ureidopropionate and β -alanine.^{36–37} This β -alanine can then serve as a precursor for synthesis of carnosine in the skeletal muscle, the brain and the heart³⁸ (see figure 1). Hence, supplementation with mineral orotates or orotic acid may represent a practical strategy for boosting the level of carnosine and carnosine derivatives within the body. Moreover, orotate may be viewed as a 'delayed release' form of β -alanine that may be better tolerated than β -alanine itself. Ingestion of β -alanine in doses greater than 800 mg at one time is often associated with 'pins and needles' paraesthesias that can last for about an hour, coinciding with an elevation of plasma β -alanine; the basis of this effect is obscure.^{3–39} Orotate supplementation, even in very high doses, does not seem to be attended by this problem, likely because the evolution of β -alanine proceeds gradually after orotate ingestion (timed-release β -alanine preparations can also be used to cope with this problem⁴⁰).

These considerations suggest that supplemental β -alanine should be evaluated in experimental and clinical cardiac disorders, and that the role of carnosine in the documented protective effects of orotates in such conditions should be assessed. Also, since the heart makes a range of histidine derivatives other than carnosine, it would be interesting to know whether supplemental histidine might impact the cardiac level of some of these. Intriguingly, there is recent evidence that supplemental histidine may be beneficial in metabolic syndrome.⁴¹

Contributors MFM wrote the first draft. JJD reviewed and edited the manuscript.

Competing interests JJD works for a company that sells nutraceuticals but he does not profit from their sales.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided

the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

- Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. *Physiol Rev* 2013;93:1803–45.
- Bonfanti L, Peretto P, De MS, *et al.* Carnosine-related dipeptides in the mammalian brain. *Prog Neurobiol* 1999;59:333–53.
- Sale C, Saunders B, Harris RC. Effect of beta-alanine supplementation on muscle carnosine concentrations and exercise performance. *Amino Acids* 2010;39:321–33.
- Everaert I, Taes Y, De HE, *et al.* Low plasma carnosinase activity promotes carnosinemia after carnosine ingestion in humans. *Am J Physiol Renal Physiol* 2012;302:F1537–44.
- Kohen R, Yamamoto Y, Cundy KC, *et al.* Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. *Proc Natl Acad Sci USA* 1988;85:3175–9.
- Pavlov AR, Revina AA, Dupin AM, *et al.* The mechanism of interaction of carnosine with superoxide radicals in water solutions. *Biochim Biophys Acta* 1993;1157:304–12.
- Kohen R, Misgav R, Ginsburg I. The SOD like activity of copper: carnosine, copper:anserine and copper:homocarnosine complexes. *Free Radic Res Commun* 1991;12–13(Pt 1):179–85.
- Baba SP, Hoetker JD, Merchant M, *et al.* Role of aldose reductase in the metabolism and detoxification of carnosine-acrolein conjugates. *J Biol Chem* 2013;288:28163–79.
- Zaloga GP, Roberts PR, Black KW, *et al.* Carnosine is a novel peptide modulator of intracellular calcium and contractility in cardiac cells. *Am J Physiol* 1997;272(1 Pt 2):H462–8.
- Dutka TL, Lamb GD. Effect of carnosine on excitation-contraction coupling in mechanically-skinned rat skeletal muscle. *J Muscle Res Cell Motil* 2004;25:203–13.
- O'Dowd JJ, Robins DJ, Miller DJ. Detection, characterisation, and quantification of carnosine and other histidyl derivatives in cardiac and skeletal muscle. *Biochim Biophys Acta* 1988;967:241–9.
- O'Dowd A, O'Dowd JJ, O'Dowd JJ, *et al.* Analysis of novel imidazoles from isolated perfused rabbit heart by two high-performance liquid chromatographic methods. *J Chromatogr* 1992;577:347–53.
- Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. *Heart* 2007;93:903–7.
- Zhao Y, Zhao B. Protective effect of natural antioxidants on heart against ischemia-reperfusion damage. *Curr Pharm Biotechnol* 2010;11:868–74.
- Stvolinsky SL, Dobrota D. Anti-ischemic activity of carnosine. *Biochemistry (Mosc)* 2000;65:849–55.
- Lee JW, Miyawaki H, Bobst EV, *et al.* Improved functional recovery of ischemic rat hearts due to singlet oxygen scavengers histidine and carnosine. *J Mol Cell Cardiol* 1999;31:113–21.
- Alabovsky VV, Boldyrev AA, Vinokurov AA, *et al.* Effect of histidine-containing dipeptides on isolated heart under ischemia/reperfusion. *Biochemistry (Mosc)* 1997;62:77–87.
- Prokop'eva VD, Laptev BI, Afanas'ev SA. [The protective effect of carnosine in hypoxia and reoxygenation of the isolated rat heart]. *Biokhimiia* 1992;57:1389–92.
- Ozdogan K, Taskin E, Dursun N. Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats. *Anadolu Kardiyol Derg* 2011;11:3–10.
- Zieba R, Wagrowska-Danilewicz M. Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. *Pol J Pharmacol* 2003;55:1079–87.
- Bokeriya LA, Boldyrev AA, Movsesyan RR, *et al.* Cardioprotective effect of histidine-containing dipeptides in pharmacological cold cardioplegia. *Bull Exp Biol Med* 2008;145:323–7.
- Bulygina ER, Kramarenko GG. [Isolation of carnosine synthetase from animal and human muscles]. *Vopr Med Khim* 1995;41:27–30.
- Heger Z, Cernei N, Kudr J, *et al.* A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. *Int J Mol Sci* 2013;14:21629–46.
- Ito T, Kimura Y, Uozumi Y, *et al.* Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. *J Mol Cell Cardiol* 2008;44:927–37.
- Usui T, Kubo Y, Akanuma S, *et al.* Beta-alanine and L-histidine transport across the inner blood-retinal barrier: potential involvement in L-carnosine supply. *Exp Eye Res* 2013;113:135–42.
- Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. *Basic Res Cardiol* 2000;95:75–83.
- Allo SN, Bagby L, Schaffer SW. Taurine depletion, a novel mechanism for cardioprotection from regional ischemia. *Am J Physiol* 1997;273(4 Pt 2):H1956–61.
- Rosenfeldt FL. Metabolic supplementation with orotic acid and magnesium orotate. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):147–52.
- Geiss KR, Stergiou N, Jester I, *et al.* Effects of magnesium orotate on exercise tolerance in patients with coronary heart disease. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):153–6.
- Branea I, Gaita D, Dragulescu I, *et al.* Assessment of treatment with orotate magnesium in early postoperative period of patients with cardiac insufficiency and coronary artery by-pass grafts (ATOMIC). *Rom J Intern Med* 1999;37:287–96.
- Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). *Int J Cardiol* 2009;134:145–7.
- Jasmin G, Proschek L. Effect of orotic acid and magnesium orotate on the development and progression of the UM-X7.1 hamster hereditary cardiomyopathy. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):189–95.
- Rosenfeldt FL, Richards SM, Lin Z, *et al.* Mechanism of cardioprotective effect of orotic acid. *Cardiovasc Drugs Ther* 1998;12(Suppl 2):159–70.
- Douban S, Brodsky MA, Whang DD, *et al.* Significance of magnesium in congestive heart failure. *Am Heart J* 1996;132:664–71.
- Dileepan KN, Kennedy J. Rapid conversion of newly-synthesized orotate to uridine-5-monophosphate by rat liver cytosolic enzymes. *FEBS Lett* 1983;153:1–5.
- Traut TW, Loechel S. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. *Biochemistry* 1984;23:2533–9.
- Naguib FN, el Kouni MH, Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. *Cancer Res* 1985;45(11 Pt 1):5405–12.
- Aonuma S, Hama T, Tamaki N, *et al.* Orotate as a beta-alanine donor for anserine and carnosine biosynthesis, and effects of actinomycin D and azauracil on their pathway. *J Biochem* 1969;66:123–32.
- Artoli GG, Gualano B, Smith A, *et al.* Role of beta-alanine supplementation on muscle carnosine and exercise performance. *Med Sci Sports Exerc* 2010;42:1162–73.
- Decombaz J, Beaumont M, Vuichoud J, *et al.* Effect of slow-release beta-alanine tablets on absorption kinetics and paresthesia. *Amino Acids* 2012;43:67–76.
- Feng RN, Niu YC, Sun XW, *et al.* Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. *Diabetologia* 2013;56:985–94.